Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
201.09(c) 203.47(c) 198.88(c) 200.8(c) 201.17(c) Last
3 197 934 2 519 902 5 400 103 3 058 566 2 858 152 Volume
-1.41% +1.18% -2.26% +0.97% +0.18% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 26 018 M - -
Net income 2021 5 551 M - -
Net Debt 2021 22 411 M - -
P/E ratio 2021 20,3x
Yield 2021 3,46%
Sales 2022 27 096 M - -
Net income 2022 7 536 M - -
Net Debt 2022 19 216 M - -
P/E ratio 2022 14,5x
Yield 2022 3,77%
Capitalization 113 B 113 B -
EV / Sales 2021 5,22x
EV / Sales 2022 4,89x
Nbr of Employees 24 300
Free-Float 99,8%
More Financials
Company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN... 
Sector
Pharmaceuticals
Calendar
02/03Earnings Release
More about the company
Ratings of Amgen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about AMGEN INC.
12/01Amgen Arthritis Drug Shows Promise as Psoriasis Medication During Phase III Testing
MT
12/01Amgen Announces Positive Top-Line Results From Otezla« (apremilast) Phase 3 DISCREET St..
PR
12/01Amgen Inc. Announces Positive Top-Line Results From Otezla? Phase 3 DISCREET Study In M..
CI
12/01Johnson & Johnson's Janssen Lands FDA Nod for Multiple Myeloma Treatment
MT
12/01Amgen Gets FDA Nod for New Kyprolis Combo Regimen for Multiple Myeloma
MT
12/01Amgen Says FDA Approves Kyprolis Combination to Treat Multiple Myeloma
DJ
11/29AMGEN : Every Patient Counts, Every Story Matters
PU
11/29Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year
PR
11/29BRISTOL-MYERS SQUIBB : Deucravacitinib Applications Advance in U.S., Europe
DJ
11/24Amgen To Present At The 2021 Evercore ISI Healthcare Conference
PR
11/24Amgen To Present At The 2021 Piper Sandler Healthcare Conference
PR
11/23AMGEN : In a First for Industry, Murielle Veniant-Ellison Honored With 2022 Havel Lectures..
PU
11/22AMGEN : Supporting Access to Nutritious Foods in Amgen's Community
PU
11/22WALL STREET STOCK EXCHANGE : Covid spike has many consequences on stock markets
11/22ANALYST RECOMMENDATIONS : Activision Blizzard, Amgen, Ebay, Vmware, Xcel Energy...
More news
News in other languages on AMGEN INC.
12/01Un médicament d'Amgen contre l'arthrite s'avère prometteur en tant que médicament contr..
12/01Janssen, filiale de Johnson & Johnson, reçoit le feu vert de la FDA pour un traitement ..
12/01Amgen reçoit l'aval de la FDA pour le nouveau traitement combiné Kyprolis contre le myé..
11/20Au procès Theranos, la fondatrice nie toute fraude et assure sa propre défense
11/12La FTC américaine approuve les modifications apportées à l'accord de cession de Bristol..
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 201,17 $
Average target price 238,86 $
Spread / Average Target 18,7%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-12.50%113 312
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726